ClinicalTrials.gg
RecruitingNCT05916391Updated Jun 23, 2023

Gene Therapy for Diabetic Macular Edema

A Phase 1 interventional study of FT-003 in Diabetic Macular Edema, sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-23.

Sponsored by Frontera Therapeutics · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 72 studies in Macular Edema with a site in China — 18 open to participants now, 22 under way, 4 of them phase 3. Macular Edema · China.

Planned enrollment
60th of 65
18 · median 140
Started
2023
with 10 others
Phase 1
9 of 72
4 open now
Primary completion
2025-05
later than 5 of 21 live
Registered
50th of 72
by date

Among the 72 studies in Macular Edema with a site in China, this one is the 60th largest by planned enrollment of the 65 interventional ones that give a count, is one of 11 that started in 2023, is one of 9 in phase 1, reaches primary completion later than 5 of the 21 other live ones, and was the 50th registered.

Macular Edema

759 studies on the registry are indexed under Macular Edema; 66 are open to participants now.

Browse Macular Edema studies →

Open to participants now

18 of the 72 studies in Macular Edema with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Macular Edema with a site in China, or all of them as a file.
02

Study summary

FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In the latest guidelines, anti-VEGF therapy is preferred for CI-DME. Administration of FT-003 has the potential to treat CI-DME by providing intraocular protein which is durable expressed in therapeutic level. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with CI-DME receiving anti-VEGF therapy in clinical practice.

03

Conditions studied

  • Diabetic Macular Edema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects that are willing and able to follow study procedures;
  • Female or male patients ≥18 years old at the time of signing the ICF;
  • Clinically diagnosed with CI-DME
  • ≤10%
  • The best corrected visual acuity (BCVA) of the studied eye is ≤ 73 letters

Exclusion criteria

Exclusion Criteria:

  • Presence of any other intraocular diseases other than CI-DME in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    FT003 Dose 1

    Low dose of FT-003

    Genetic: FT-003

  • Experimental
    FT003 Dose 2

    Mid dose of FT-003

    Genetic: FT-003

  • Experimental
    FT003 Dose 3

    High dose of FT-003

    Genetic: FT-003

Interventions

  • GeneticFT-003

    Administration via intraocular injection

06

What researchers measure

Primary outcomes

  1. Safety and tolerability after FT-003 injection

    Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)

    Time frame: Whthin 52 weeks after administration

Secondary outcomes

  1. Preliminary effectiveness after FT-003 injection

    Changes in best-corrected visual acuity (BCVA) of the studied eye from baseline

    Time frame: Whthin 52 weeks after administration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2025, 23 months after the start.

Of 25 phase 1 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 51. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2023
First posted
Jun 23, 2023
StartActual
May 19, 2023
Primary completionEst.
May 1, 2025
CompletionEst.
May 1, 2028
Last update
Jun 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05916391
Lead sponsor
Frontera Therapeutics
Responsible party
Sponsor
First posted
Jun 23, 2023
Start date
May 19, 2023
Primary completion
May 1, 2025 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Jun 23, 2023

Study contacts

Xinyan Li
Contact
Xinyan.li@fronteratherapeutics.com
+862158206061
Minghui Xue
Contact
minghui.xue@fronteratherapeutics.com
+862158206061
Xiaorong Li, Professor
principal investigator · Tianjin Medical University Eye Hospital
Hanyi Min, Professor
principal investigator · Peking Union Medical College Hospital
Guangming Wan, Professor
principal investigator · The First Affiliated Hospital of Zhengzhou University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion